ZBD | $40,000,000 | (Jan 23, 2026)
Allocation Strategy | $2,164,392 | (Jan 23, 2026)
Asymmetric Security | $4,200,000 | (Jan 23, 2026)
Certified by Founder
Lodge
CellFE
start up
United States
- Alameda, California
- 28/09/2023
- Series A
- $22,000,000
CellFE is a cell engineering startup that enables development and manufacturing of the new generation of medicines – cell therapies. CellFE has developed a unique microfluidic platform to solve one of the most pressing issues of therapeutic cell engineering –efficiently delivering gene-editing molecules into cells while preserving cell viability. CellFE’s technology:
• Enables development of previously inaccessible cell therapies by providing means for transporting hard-to-deliver molecules into the cells.
• Accelerates commercialization of existing cell therapies by significantly reducing cost, complexity, and processing time, while improving the efficacy and safety of the cell engineering process.
- Industry Biotechnology
- Website https://www.cellfebiotech.com/
- LinkedIn https://www.linkedin.com/company/cellfe-biotech/about/
Cubby | $63,000,000 | (Jan 23, 2026)
Cambio | $18,000,000 | (Jan 23, 2026)
Cork Protocol | $5,500,000 | (Jan 23, 2026)
Yuki | $6,000,000 | (Jan 23, 2026)
Mia Labs | $20,000,000 | (Jan 23, 2026)
Mendra | $82,000,000 | (Jan 23, 2026)
Artie Technologies | $12,000,000 | (Jan 23, 2026)
Antidote Legal | $5,000,000 | (Jan 23, 2026)
One to One Health | $12,000,000 | (Jan 22, 2026)